Erasca, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ERAS-0015, an investigational oral pan-RAS molecular glue, for the treatment of patients with metastatic pancreatic adenocarcinoma.
The designation recognizes the urgent need for new treatment options in metastatic pancreatic cancer, a disease where therapeutic advances remain limited and outcomes continue to be among the poorest across solid tumors.
ERAS-0015 is designed to inhibit RAS signaling, targeting a central pathway involved in tumor growth and cancer progression. The therapy is being developed by Erasca as part of its precision oncology strategy focused on cancers driven by the RAS/MAPK pathway.
FDA Fast Track Designation Supports Accelerated Development
FDA Fast Track Designation is granted to therapies addressing serious conditions with significant unmet medical needs and is intended to facilitate more frequent communication between developers and the FDA during clinical development.
Programs receiving this designation may benefit from opportunities such as increased interactions with regulatory authorities and potential eligibility for mechanisms including accelerated approval, priority review, and rolling review if applicable criteria are met.
For ERAS-0015, the designation follows encouraging early clinical activity observed in patients with advanced cancers, including individuals with second-line or later KRAS G12X pancreatic ductal adenocarcinoma (PDAC).
Encouraging Early Clinical Activity in KRAS G12X Pancreatic Cancer
Updated preliminary findings from the AURORAS-1 Phase 1 trial demonstrated encouraging clinical activity with ERAS-0015 monotherapy in patients with previously treated KRAS G12X pancreatic cancer.
Among patients receiving the recommended dose for expansion of 32 mg once daily, the study reported a 57% unconfirmed overall response rate at eight weeks (uORR8wk) in the second-line or later KRAS G12X PDAC population.
All responding patients remained on treatment at the time of the data cutoff, and ERAS-0015 continued to demonstrate a favorable tolerability profile.
Advancing Toward Potential Registration-Enabling Studies
Following the FDA designation, Erasca plans to continue advancing ERAS-0015 development, including a planned Phase 3 trial in pancreatic cancer and additional potentially registration-enabling studies in lung cancer.
The company also expects additional monotherapy and combination data from the AURORAS-1 trial, including combination cohorts involving panitumumab, in the first half of 2027.
Targeting the RAS/MAPK Pathway Through a New Therapeutic Strategy
ERAS-0015 represents a novel approach to targeting RAS-driven cancers. The investigational therapy is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling and potentially address limitations associated with selective RAS inhibition strategies.
According to Erasca, early dose escalation data from AURORAS-1 demonstrated favorable safety and tolerability, linear pharmacokinetic properties, and partial responses across multiple tumor types and different RAS mutations.
A Potential Step Forward for Patients With RAS-Driven Pancreatic Cancer
Pancreatic adenocarcinoma remains one of the most difficult cancers to treat, particularly in the metastatic setting where treatment options are limited and durable responses remain challenging.
The FDA Fast Track Designation for ERAS-0015 marks an important milestone in the ongoing effort to develop new precision therapies for patients whose cancers are driven by RAS pathway alterations.
While further clinical evaluation is required to determine the long-term efficacy and safety profile of ERAS-0015, the emerging data highlight continued progress in developing targeted approaches against one of the most historically difficult cancer pathways.
Discover more articles like this on OncoDaily